ClinicalTrials.gg
CompletedNCT03106779Updated Aug 18, 2026Results posted

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Phase 3 interventional study of Asciminib and Bosutinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 88 sites in 25 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
5th of 21
233 · median 100
Started
2017
the only one that year
Phase 3
5 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
12 of 21
Novartis Pharmaceuticals

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 3, and was the 2nd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).

Read the detailed description

Participants with a diagnosis of CML-CP who had received prior treatment with 2 or more ATP binding site TKIs and were treatment failure (as per guidelines adapted from the 2013 ELN recommendations) or intolerant to the most recent TKI.

Participants were randomized in a 2:1 ratio to asciminib 40 mg BID or bosutinib 500 mg QD. Randomization was stratified by major cytogenetic response (MCyR) at screening.

Participants with documented treatment failure (as per the 2013 ELN recommendations) while on bosutinib treatment were offered the option to switch to asciminib treatment within 96 weeks after the last patient was randomized to the study.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • Phase 3
  • Chronic Myelogenous Leukemia
  • CML
  • bosutinib
  • ABL001
  • tyrosine kinase inhibitor
  • Chronic myelogenous leukemia (CML)
  • chronic myeloid leukemia (CML)
  • chronic myelocytic leukemia (CML)
  • chronic granulocytic leukemia (CGL)
  • cancer of the white blood cells
  • clonal bone marrow stem cell disorder
  • proliferation of mature granulocytes
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female patients with a diagnosis of CML-CP ≥ 18 years of age

Patients must meet all of the following laboratory values at the screening visit:

  • \< 15% blasts in peripheral blood and bone marrow
  • \< 30% blasts plus promyelocytes in peripheral blood and bone marrow
  • \< 20% basophils in the peripheral blood
  • ≥ 50 x 109/L (≥ 50,000/mm3)
  • Transient prior therapy related thrombocytopenia (\< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly

BCR-ABL1 ratio > 0.1% IS according to central laboratory at the screening examination for patients intolerant to the most recent TKI therapy

Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, nilotinib, dasatinib, radotinib or ponatinib)

Failure (adapted from the 2013 ELN Guidelines Bacarrani 2013) or intolerance to the most recent TKI therapy at the time of screening

  • Failure is defined for CML-CP patients (CP at the time of initiation of last therapy) as follows. Patients must meet at least 1 of the following criteria.
  • Three months after the initiation of therapy: No CHR or > 95% Ph+ metaphases
  • Six months after the initiation of therapy: BCR-ABL1 ratio > 10% IS and/or > 65% Ph+ metaphases
  • Twelve months after initiation of therapy: BCR-ABL1 ratio > 10% IS and/or > 35% Ph+ metaphases
  • At any time after the initiation of therapy, loss of CHR, CCyR or PCyR
  • At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment
  • At any time after the initiation of therapy, confirmed loss of MMR in 2 consecutive tests, of which one must have a BCR-ABL1 ratio ≥ 1% IS
  • At any time after the initiation of therapy, new clonal chromosome abnormalities in Ph+ cells: CCA/Ph+
  • Intolerance is defined as:
  • Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)
  • Hematologic intolerance: Patients with grade 3 or 4 toxicity ( [ANC] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer

Exclusion criteria

Exclusion Criteria:

Known presence of the T315I or V299L mutation at any time prior to study entry Known second chronic phase of CML after previous progression to AP/BC Previous treatment with a hematopoietic stem-cell transplantation Patient planning to undergo hematopoietic stem cell transplantation

Cardiac or cardiac repolarization abnormality, including any of the following:

  • History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
  • cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
  • at screening ≥450 msec (male patients), ≥460 msec (female patients)
  • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
  • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
  • Concomitant medication(s) with a known risk of Torsades de Pointes per www.crediblemeds.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
  • Inability to determine the QTcF interval
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension)
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • History of acute or chronic liver disease
  • Treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with study treatment
  • Moderate or strong inducers of
  • Moderate or strong inhibitors of CYP3A
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 3 days after last dose of ABL001 and one month after last dose of bosutinib. Highly effective contraception methods include:
  • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy (with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject.
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
  • In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
  • Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study medication. In the case of oophorectomy alone, women are considered post-menopausal and not of child bearing potential only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Asciminib

    Patients were randomized to asciminib 40mg BID

    Drug: Asciminib

  • Active comparator
    Bosutinib

    Patients were randomized to bosutinib 500mg QD

    Drug: Bosutinib

Interventions

  • 40 mg tablets was taken orally twice a day (BID)

    Also known as: ABL001

  • 500 mg tablets was taken orally once daily (QD)

06

What researchers measure

Primary outcomes

  1. Major Molecular Response (MMR) Rate at 24 Weeks

    MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

    Time frame: 24 weeks

Secondary outcomes

  1. Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)

    MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

    Time frame: 96 Weeks

  2. Complete Cytogenetic Response (CCyR) Rate at Scheduled Time Points

    Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.

    Time frame: at 24, 48, 72, 96, 120 and 144 weeks

  3. Complete Cytogenetic Response Rate by Scheduled Time Points

    Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.

    Time frame: by 24, 48, 72, 96, 120 and 144 weeks

  4. Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96

    MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

    Time frame: at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156

  5. Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points

    MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.

    Time frame: by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall

  6. Time to Major Molecular Response (MMR)

    Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.

    Time frame: 216 Weeks

  7. Duration of Major Molecular Response (MMR)

    Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.

    Time frame: 216 Weeks

  8. Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR

    Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.

    Time frame: 216 Weeks

  9. Duration of Complete Cytogenetic Response (CCyR)

    Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.

    Time frame: 144 weeks

  10. Time to Treatment Failure (TTF)

    TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.

    Time frame: From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately

  11. Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates

    Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.

    Time frame: From the first dose of treatment up to study completion, up to 5 years

  12. Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates

    Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).

    Time frame: From the first dose of treatment to study completion, up to 5 years

  13. Trough Plasma Concentrations for Asciminib

    Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)

    Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

  14. PK Parameter: Cmax for Asciminib

    Maximum (peak) observed plasma concentration after dose administration (mass x volume-1).

    Time frame: Week 2 Day 1 at pre-dose, 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

  15. PK Parameter: Tmax for Asciminib

    Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.

    Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

  16. PK Parameter: AUC0-12h for Asciminib

    Area under the plasma concentration-time curve from time zero to 12 hours (mass x time x volume-1)

    Time frame: Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

  17. PK Parameter: CL/F for Asciminib

    Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).

    Time frame: Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

07

Results

Posted Feb 15, 2022

Participant flow

Participants were treated at a total of 84 sites.

Participant flow — Overall Study
MilestoneAsciminibBosutinib
Started15776
Treated15676
Not treated10
Switched to receive asciminib025
Completed778
Not completed8068
Withdrew: Lack of efficacy4028
Withdrew: Physician decision137
Withdrew: Adverse event1121
Withdrew: Subject/guardian decision67
Withdrew: Death40
Withdrew: Progressive disease23
Withdrew: Lost to follow-up12
Withdrew: Pregnancy10
Withdrew: Protocol violation10
Withdrew: Not treated10

Outcome measures

PrimaryMajor Molecular Response (MMR) Rate at 24 Weeks

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

Time frame:
24 weeks
Reported as:
Number · Percentage of participants
Major Molecular Response (MMR) Rate at 24 Weeks
Percentage of participantsAsciminibBosutinib
Major Molecular Response (MMR) Rate at 24 Weeks25.4813.16
Statistical analysis
  • Asciminib vs Bosutinib · Cochran-Mantel-Haenszel · p = 0.029 · Treatment difference in the mmr rate: 12.2 · 95% CI 2.19 to 22.30Stratified by the randomization stratification factor, i.e. cytogenetic response status (MCyR vs no MCyR) at screening
SecondaryMajor Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)

MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

Time frame:
96 Weeks
Reported as:
Number · Percentage of participants
Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)
Percentage of participantsAsciminibBosutinib
Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)37.5815.79
Statistical analysis
  • Asciminib vs Bosutinib · Cochran-Mantel-Haenszel · p = 0.001 · Cochran-mantel- haenszel chi-square test: 21.74 · 95% CI 10.53 to 32.95
SecondaryComplete Cytogenetic Response (CCyR) Rate at Scheduled Time Points

Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.

Time frame:
at 24, 48, 72, 96, 120 and 144 weeks
Reported as:
Count of participants · Participants
Complete Cytogenetic Response (CCyR) Rate at Scheduled Time Points
ParticipantsAsciminibBosutinib
at Week 244215
at Week 484113
at Week 723912
at Week 964110
at Week 120377
at Week 144354
SecondaryComplete Cytogenetic Response Rate by Scheduled Time Points

Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.

Time frame:
by 24, 48, 72, 96, 120 and 144 weeks
Reported as:
Count of participants · Participants
Complete Cytogenetic Response Rate by Scheduled Time Points
ParticipantsAsciminibBosutinib
by Week 244215
by Week 484722
by Week 724922
by Week 965122
by Week 1205122
by Week 1445122
SecondaryMajor Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.

Time frame:
at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156
Reported as:
Count of participants · Participants
Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96
ParticipantsAsciminibBosutinib
at Week 36419
at Week 484610
at Week 605211
at Week 725212
at Week 845010
at Week 1085311
at Week 120578
at Week 132588
at Week 144597
at Week 156538
SecondaryMajor Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.

Time frame:
by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall
Reported as:
Count of participants · Participants
Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points
ParticipantsAsciminibBosutinib
by Week 430
by Week 8124
by Week 12307
by Week 16398
by Week 244311
by Week 365113
by Week 485515
by Week 606016
by Week 726017
by Week 846317
by Week 966718
by Week 1086718
by Week 1206818
by Week 1327018
by Week 1447118
by Week 1567118
Overall7419
SecondaryTime to Major Molecular Response (MMR)

Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.

Time frame:
216 Weeks
Reported as:
Median · Weeks
Time to Major Molecular Response (MMR)
WeeksAsciminibBosutinib
Time to Major Molecular Response (MMR)16.3 (4 to 216)24.1 (7 to 216)
SecondaryDuration of Major Molecular Response (MMR)

Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.

Time frame:
216 Weeks
Reported as:
Median · Weeks
Duration of Major Molecular Response (MMR)
WeeksAsciminibBosutinib
Duration of Major Molecular Response (MMR)NA (NA to NA)NA (NA to NA)
SecondaryTime to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR

Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.

Time frame:
216 Weeks
Reported as:
Median · Weeks
Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR
WeeksAsciminibBosutinib
Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR24.3 (23 to 216)24.3 (12 to 53)
SecondaryDuration of Complete Cytogenetic Response (CCyR)

Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.

Time frame:
144 weeks
Reported as:
Median · Weeks
Duration of Complete Cytogenetic Response (CCyR)
WeeksAsciminibBosutinib
Duration of Complete Cytogenetic Response (CCyR)NA (NA to NA)NA (64.1 to NA)
SecondaryTime to Treatment Failure (TTF)

TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.

Time frame:
From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately
Reported as:
Median · Year
Time to Treatment Failure (TTF)
YearAsciminibBosutinib
Time to Treatment Failure (TTF)2.4 (1.0 to NA)0.5 (0.5 to 0.6)
SecondaryProgression Free Survival Per Percentage Event-free Kaplan-Meier Estimates

Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.

Time frame:
From the first dose of treatment up to study completion, up to 5 years
Reported as:
Number · Percentage of participants
Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
Percentage of participantsAsciminibBosutinib
1 year95.6 (90.4 to 98.0)91.4 (80.2 to 96.4)
3 years85.7 (77.5 to 91.0)84.9 (69.6 to 92.9)
5 years68.5 (47.2 to 82.7)64.6 (38.4 to 81.9)
SecondaryOverall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates

Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).

Time frame:
From the first dose of treatment to study completion, up to 5 years
Reported as:
Number · Percentage of participants
Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates
Percentage of participantsAsciminibBosutinib
1 year97.3 (92.9 to 99.0)98.6 (90.2 to 99.8)
3 years92.4 (86.7 to 95.7)96.9 (88.0 to 99.2)
5 years89.4 (83.1 to 93.5)90.0 (78.9 to 95.4)
SecondaryTrough Plasma Concentrations for Asciminib

Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)

Time frame:
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Reported as:
Median · ng/mL
Trough Plasma Concentrations for Asciminib
ng/mLAsciminib
Trough Plasma Concentrations for Asciminib238 (145 to 551)
SecondaryPK Parameter: Cmax for Asciminib

Maximum (peak) observed plasma concentration after dose administration (mass x volume-1).

Time frame:
Week 2 Day 1 at pre-dose, 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Reported as:
Geometric mean · ng/mL
PK Parameter: Cmax for Asciminib
ng/mLAsciminib
PK Parameter: Cmax for Asciminib971 ± 48.3
SecondaryPK Parameter: Tmax for Asciminib

Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.

Time frame:
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Reported as:
Median · hour (hr)
PK Parameter: Tmax for Asciminib
hour (hr)Asciminib
PK Parameter: Tmax for Asciminib1.92 (0.983 to 3.33)
SecondaryPK Parameter: AUC0-12h for Asciminib

Area under the plasma concentration-time curve from time zero to 12 hours (mass x time x volume-1)

Time frame:
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Reported as:
Geometric mean · ng*hr/mL
PK Parameter: AUC0-12h for Asciminib
ng*hr/mLAsciminib
PK Parameter: AUC0-12h for Asciminib5810 ± 32.9
SecondaryPK Parameter: CL/F for Asciminib

Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).

Time frame:
Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
Reported as:
Median · L/hr
PK Parameter: CL/F for Asciminib
L/hrAsciminib
PK Parameter: CL/F for Asciminib7.29 (3.73 to 11.5)

Adverse events

Collected over Adverse events (AEs) & on-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication. The maximum duration of treatment exposure was 256.3 weeks for asciminib, and 239.3 weeks for bosutinib.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-treatment Period Asciminib5/156 (3.2%)34/156 (21.8%)130/156 (83.3%)
On-treatment Period Bosutinib1/76 (1.3%)20/76 (26.3%)72/76 (94.7%)
On-treatment Period: Switched From Bosutinib to Asciminib0/25 (0%)2/25 (8%)20/25 (80%)
Post-treatment Period Asciminib11/135 (8.1%)1/135 (0.7%)7/135 (5.2%)
Post-treatment Period Bosutinib8/61 (13.1%)0/61 (0%)3/61 (4.9%)
Post-treatment Period: Switched From Bosutinib to Asciminib3/24 (12.5%)0/24 (0%)0/24 (0%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventOn-treatment Period AsciminibOn-treatment Period BosutinibOn-treatment Period: Switched From Bosutinib to AsciminibPost-treatment Period AsciminibPost-treatment Period BosutinibPost-treatment Period: Switched From Bosutinib to Asciminib
Abdominal painGastrointestinal disorders1/1560/761/250/1350/610/24
Mesenteric arterial occlusionGastrointestinal disorders0/1560/761/250/1350/610/24
Mesenteric artery thrombosisGastrointestinal disorders1/1560/761/250/1350/610/24
Cholecystitis acuteHepatobiliary disorders0/1560/761/250/1350/610/24
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1560/761/250/1350/610/24
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1560/761/250/1350/610/24
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1563/760/250/1350/610/24
RashSkin and subcutaneous tissue disorders0/1562/760/250/1350/610/24
Cardiac failureCardiac disorders3/1560/760/250/1350/610/24
Urinary tract infectionInfections and infestations3/1560/760/250/1350/610/24
Most frequent other events
Showing 10 of 47
Most frequent other events
EventOn-treatment Period AsciminibOn-treatment Period BosutinibOn-treatment Period: Switched From Bosutinib to AsciminibPost-treatment Period AsciminibPost-treatment Period BosutinibPost-treatment Period: Switched From Bosutinib to Asciminib
DiarrhoeaGastrointestinal disorders20/15655/761/250/1350/610/24
NauseaGastrointestinal disorders18/15635/764/250/1350/610/24
NeutropeniaBlood and lymphatic system disorders30/15613/769/251/1350/610/24
ThrombocytopeniaBlood and lymphatic system disorders36/15611/768/252/1350/610/24
Alanine aminotransferase increasedInvestigations8/15623/761/250/1352/610/24
VomitingGastrointestinal disorders12/15619/762/250/1350/610/24
RashSkin and subcutaneous tissue disorders15/15617/762/251/1350/610/24
Aspartate aminotransferase increasedInvestigations9/15616/761/250/1351/610/24
HeadacheNervous system disorders30/15612/764/251/1350/610/24
Abdominal painGastrointestinal disorders14/15612/761/250/1350/610/24

Baseline characteristics

Full Analysis Set (FAS): The FAS comprised of all randomized patients.

Age, Continuous
Age, Continuous(years)AsciminibBosutinibTotal
Mean51.0 ± 13.4951.0 ± 13.9551.0 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)AsciminibBosutinibTotal
Female7545120
Male8231113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AsciminibBosutinibTotal
White11856174
Asian221133
Black or African American8210
American Indian or Alaska Native101
Other5712
Unknown303
08

Study locations

88 sites
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Indiana Blood and Marrow Institute
    Beech Grove, Indiana 46107, United States
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21205, United States
  • Dana Farber Cancer Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Clinical Trials Office
    Ann Arbor, Michigan 48109, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medicine NY-Presb
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Ctr
    New York, New York 10065, United States
  • Uni Of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Utah Huntsman Cancer Center
    Salt Lake City, Utah 84112, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1221ADH, Argentina
  • Novartis Investigative Site
    Capital Federal, C1114AAN, Argentina
  • Novartis Investigative Site
    Córdoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 20211-030, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 05403 000, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 08270-070, Brazil
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Varna, 9000, Bulgaria
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Kiel, 24116, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, H-1097, Hungary
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Ẕerifin, 7030000, Israel
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 453-8511, Japan
  • Novartis Investigative Site
    Toyoake, Aichi-ken 4701192, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Kobe, Hyōgo 650-0017, Japan
  • Novartis Investigative Site
    Sakai, Osaka 590-0197, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138677, Japan
  • Novartis Investigative Site
    Chūō, Yamanashi 409-3898, Japan
  • Novartis Investigative Site
    Akita, 0108543, Japan
  • Novartis Investigative Site
    Aomori, 0308553, Japan
  • Novartis Investigative Site
    Beirut, 1100 2070, Lebanon
  • Novartis Investigative Site
    Beirut, 113-0236, Lebanon
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Amsterdam, North Holland 1081 HV, Netherlands
  • Novartis Investigative Site
    Dordrecht, South Holland 3318 AT, Netherlands
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400015, Romania
  • Novartis Investigative Site
    Timișoara, 300079, Romania
  • Novartis Investigative Site
    Moscow, 125167, Russia
  • Novartis Investigative Site
    Moscow, 125284, Russia
  • Novartis Investigative Site
    Saint Petersburg, 191024, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russia
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Belgrade, 11000, Serbia
  • Novartis Investigative Site
    Novi Sad, 400107, Serbia
  • Novartis Investigative Site
    Uijeongbu-si, Gyeonggi-do 11759, South Korea
  • Novartis Investigative Site
    Busan, 49201, South Korea
  • Novartis Investigative Site
    Jeollanam, 519763, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Bilbao, Bizkaia 48013, Spain
  • Novartis Investigative Site
    Toledo, Castille-La Mancha 45071, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Samsun, Atakum 55200, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Adana, Saricam 01330, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
  • Novartis Investigative Site
    Metropolitan Borough of Wirral, Merseyside CH63 4JY, United Kingdom
  • Novartis Investigative Site
    Cardiff, CF14 4XW, United Kingdom
  • Novartis Investigative Site
    Glasgow, G12 0YN, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Mauro MJ, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz N, Dhamal V, Rea D. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Adv. 2025 Aug 26;9(16):4248-4259. doi: 10.1182/bloodadvances.2025016042. PubMed 40334072 ↗
  • Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jan-Dec;26(1):915-923. doi: 10.1080/13696998.2023.2234776. PubMed 37431294 ↗
  • Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Matsumura I, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Allepuz A, Minami Y. Asciminib vs bosutinib in CML patients pretreated with >/=2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Med. 2023 Feb;12(3):2990-2998. doi: 10.1002/cam4.5212. Epub 2022 Sep 27. PubMed 36168187 ↗
  • Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. Clin Pharmacokinet. 2022 Oct;61(10):1393-1403. doi: 10.1007/s40262-022-01148-9. Epub 2022 Jun 28. PubMed 35764773 ↗
  • Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. PubMed 34407542 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in May 2020, 30 months.

Results were first posted in Feb 2022, 1 year 8 months after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2017
First posted
Apr 10, 2017
StartActual
Oct 26, 2017
Primary completionActual
May 25, 2020
CompletionActual
Dec 4, 2024
Results first posted
Feb 15, 2022
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03106779
Responsible party
Sponsor
First posted
Apr 10, 2017
Start date
Oct 26, 2017
Primary completion
May 25, 2020
Completion
Dec 4, 2024
Results posted
Feb 15, 2022
Last update
Aug 18, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion